期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 117, 期 8, 页码 2051-2058出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI32278
关键词
-
资金
- NCI NIH HHS [CA089481, CA055306, P01 CA089480, R01 CA055306, R01 CA089481, CA089480] Funding Source: Medline
Understanding the genetic origin of cancer at the molecular level has facilitated the development of novel targeted therapies. Aberrant activation of the ErbB family of receptors is implicated in many human cancers and is already the target of several anticancer therapeutics. The use of mAbs specific for the extracellular domain of ErbB receptors was the first implementation of rational targeted therapy. The cytoplasmic tyrosine kinase domain is also a preferred target for small compounds that inhibit the kinase activity of these receptors. However, current therapy has not yet been optimized, allowing for opportunities for optimization of the next generation of targeted therapy, particularly with regards to inhibiting heteromeric ErbB family receptor complexes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据